Bioventus Inc. (BVS) Stock Price & Analysis
Bioventus Inc. (BVS) rose 2.79% to USD 11.8 as of July 25, 2026 at 07:27 UTC, according to Nexqual real-time market data.
BVS last closed at USD 11.48; the session ranged USD 11.6–11.91 on volume of 464,346 shares. Market capitalization is $799.43M, with a 52-week range of USD 5.81–12.53 (NMS). Source: Nexqual, July 25, 2026 at 07:27 UTC.
Key Statistics (as of July 25, 2026 at 07:27 UTC)
| Price | USD 11.8 |
|---|---|
| Change | ▲ 2.79% (up) |
| Previous Close | USD 11.48 |
| Open | USD 11.67 |
| Day Range | USD 11.6 – 11.91 |
| 52-Week Range | USD 5.81 – 12.53 |
| Volume | 464,346 shares |
| Market Cap | $799.43M |
| Exchange | NMS |
Technical Analysis (BVS)
Nexqual's technical model rates BVS "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.38 (neutral) |
| vs SMA50 | Above (USD 10.08) |
| MACD | 0.56 (positive) |
Analyst Ratings (BVS)
Wall Street analysts rate BVS "None" based on 5 analysts, with a mean price target of USD 14.8 (range USD 14–16), per Nexqual as of July 25, 2026 at 07:27 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 14.8 |
| High Target | USD 16 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (BVS)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.22 |
| Revenue Estimate | $155.64M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.15 vs est 0.07 ▲ beat |
| 2025-12-31 | USD 0.24 vs est 0.22 ▲ beat |
| 2025-09-30 | USD 0.15 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.21 vs est 0.2 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:27 UTC.
Financials & Fundamentals (BVS)
| Total Revenue | $576.30M |
|---|---|
| Revenue Growth (YoY) | +6.60% |
| Gross Margin | +68.69% |
| Operating Margin | +6.73% |
| Profit Margin | +4.94% |
| ROE | +16.46% |
| Debt / Equity | 123.12 |
| Current Ratio | 1.69 |
| Total Cash | $35.85M |
| Total Debt | $288.42M |
| Free Cash Flow | $63.31M |
Source: Nexqual, July 25, 2026 at 07:27 UTC.
Financial Health Score (BVS)
Nexqual rates Bioventus Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:27 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 7% |
| Balance Sheet | Mixed — $36M cash vs $288M debt |
| Cash Flow | Solid — FCF $63M, 11% margin |
| Efficiency | Solid — ROE 16%, ROA 5.6% |
Ownership (BVS)
| Insider Ownership | +11.75% |
|---|---|
| Institutional Ownership | +78.36% |
| Shares Outstanding | 67.75M |
| Float | 33.31M |
| Short % of Float | +5.89% |
Source: Nexqual, July 25, 2026 at 07:27 UTC.
Leadership (BVS)
Bioventus Inc. is led by Robert E. Claypoole (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 07:27 UTC.
| President, CEO & Director | Robert E. Claypoole (age 53) |
|---|---|
| Senior VP & CFO | Mark L. Singleton (age 56) |
| Senior Vice President of Operations | Mike Crowe B.S. |
| Vice President of Investor Relations & Treasurer | David Crawford |
Major Backers & Investors (BVS)
Notable institutional backers of Bioventus Inc. include Essex Woodlands Management Inc., Juniper Investment Company, LLC, Nantahala Capital Management, LLC, according to Nexqual as of July 25, 2026 at 07:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Essex Woodlands Management Inc. | 19.22% |
| Juniper Investment Company, LLC | 10.24% |
| Nantahala Capital Management, LLC | 9.04% |
| Royce & Associates LP | 2.28% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 1.65% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.85% |
| Vanguard Group | 6.45% |
| Geode Capital | 1.72% |
| State Street | 1.46% |
Source: Nexqual, July 25, 2026 at 07:27 UTC.
From Bioventus Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
- It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
- The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products.
- Its products also include Exogen, an ultrasound bone stimulation system.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVAH | Aveanna Healthcare Holdings Inc | USD 9.45 | ▲ 0.21% |
| ANNX | Annexon, Inc. | USD 5.22 | ▼ 0.19% |
| TMCI | Treace Medical Concepts, Inc. | USD 4 | ▲ 0.76% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:27 UTC. This page is informational and not investment advice.